Objective: The goal of the present study was to investigate the effects of 5-lipoxygenase (5-LOX) inhibition, alone and with cyclooxygenase (COX) inhibitors, on inflammatory parameters and apoptosis in ischemia/reperfusion (I/R)-induced myocardial damage in rats. For this purpose, zileuton, a selective and potent inhibitor of 5-LOX, resulting in suppression leukotriene production, was used. Methods: Male Wistar rats (200-250 g; n=12 per group) were used in the study. I/R was performed by occluding the left coronary artery for 30 minu-tes and 2 hours of reperfusion of the heart. Experimental groups were I/R group, sham I/R group, zileuton (5 mg/kg orally, twice daily)+I/R group, zileuton+indomethacin (5 mg/kg intraperitoneally)+I/R group, zileuton+ketorolac (10 mg/kg subcutaneously)+I/R group, and zileuton+nimesulide (5 mg/kg subcutaneously)+I/R group. Following I/R, blood samples were collected to measure tumor necrosis factor alpha (TNF-alpha), and left ventric-les were excised for evaluation of microscopic damage; malondialdehyde (MDA), glutathione, nuclear factor (NF)-kappa B assays; and evaluation of apoptosis. Results: Left ventricle MDA in I/R group was higher compared to sham group; however, it did not show significant change with zileuton. Although tissue injury in I/R group was less severe in all treatment groups, it was not statistically significant. NF-kappa B H-score and apoptotic index, which were higher in I/R group compared to sham I/R, were decreased with application of zileuton (H-score: p<0.01; apoptotic index: p<0.001). Zileuton had no significant effect on increased serum TNF-alpha levels in I/R group. Conclusion: 5-LOX inhibition in rat myocardial infarction model attenuated increased left ventricle NF-kappa B expression and apoptosis and these actions were not modulated by COX inhibitors.
机构:
SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406
ALBRIGHTSON, CR
SHORT, B
论文数: 0引用数: 0
h-index: 0
机构:
SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406
SHORT, B
DYTKO, G
论文数: 0引用数: 0
h-index: 0
机构:
SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406
DYTKO, G
ZABKOPOTAPOVICH, B
论文数: 0引用数: 0
h-index: 0
机构:
SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406
ZABKOPOTAPOVICH, B
BRICKSON, B
论文数: 0引用数: 0
h-index: 0
机构:
SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406
BRICKSON, B
ADAMS, JL
论文数: 0引用数: 0
h-index: 0
机构:
SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406
ADAMS, JL
GRISWOLD, DE
论文数: 0引用数: 0
h-index: 0
机构:
SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM & TOXICOL,KING OF PRUSSIA,PA 19406